Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), announced that its self-developed drug Hanbeitai® (Bevacizumab Injection) has received acceptance for its Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) [1] Summary by Categories Product Development - The BLA application includes indications for multiple cancers: 1. Metastatic colorectal cancer 2. First-line treatment of unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel 3. Recurrent adult glioblastoma 4. Metastatic renal cell carcinoma in combination with interferon α 5. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 6. Persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan [1]

格隆汇1月13日｜中信建投证券研报指出，荣昌生物与艾伯维就RC148（PD1/VEGF）实现全球合作，整 体交易的首付款为6.5亿美元，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，同时 还拥有在大中华地区以外的净销售额的两位数分级特许权使用费，首付款和总金额超出市场预期。具体 来看，RC148此前在1L NSCLC和后线NSCLC中均展现出优异临床数据，药物目前在多个实体瘤中开展 临床研究，未来可期。认为本次合作让公司的国际化得到进一步加强，看好公司未来发展。预计2025- 2027年，公司收入分别为24.55亿元、33.88亿元和45.74亿元，维持"买入"评级。（暂不考虑BD的收入 确认影响） ...

Core Viewpoint - The company has initiated the "Thousand Mice, Ten Thousand Antibodies" program to develop antibodies targeting over 1,000 potential drug targets, leveraging AI technology to enhance its research and development capabilities [1] Group 1: Company Initiatives - The "Thousand Mice, Ten Thousand Antibodies" program was launched in 2020, focusing on developing antibodies using platforms like RenMab, RenLite, and RenNano [1] - By the end of 2024, the company aims to have obtained approximately 1,000,000 fully human antibody sequences, covering various forms such as monoclonal, bispecific, and nanobodies [1] - The company plans to expand its fully human antibody library to tens of millions in the future [1] Group 2: AI Integration - The company has completed the localized deployment of an AI-driven antibody drug development platform, which is fully integrated with the "Thousand Mice, Ten Thousand Antibodies" program [1] - An "antibody evolution tree" has been established, encompassing over 1,000 targets and 1,000,000 fully human antibody molecules, utilizing bioinformatics [1] - The ongoing integration of the "Thousand Mice, Ten Thousand Antibodies" program with the AI system is expected to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library [1]

Group 1 - The core point of the news is the significant licensing agreement between Rongchang Biopharma and AbbVie for the development and commercialization of RC148, a novel bispecific antibody targeting PD-1 and VEGF, which could lead to substantial financial benefits for Rongchang Biopharma [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with double-digit royalties on net sales outside Greater China [1] - The deal exemplifies the "China innovation + global market" model in drug development, indicating a growing trend of collaboration between Chinese biotech firms and international pharmaceutical companies [1] Group 2 - In 2024, U.S. pharmaceutical companies significantly increased their acquisition of Chinese innovative drugs, with a year-on-year growth of 66%, leading to a total licensing transaction value of $41.5 billion [2] - Recently, five business development projects have been established in a short period, covering various fields such as small molecule inhibitors, monoclonal antibodies, bispecific antibodies, ADCs, and RDCs, indicating a flourishing environment for Chinese innovative drugs [2] - The Hong Kong innovation drug sector is showing signs of recovery, with the Hang Seng Innovation Drug Index having corrected approximately 25% since its peak in September 2025, but is now rebounding [3] Group 3 - The U.S. biotech sector, particularly the Nasdaq Biotechnology Index, has reached new highs, increasing by 23% since September of last year, highlighting a disparity in performance compared to the Hong Kong innovation drug sector [5] - The recent surge in business development projects serves as a catalyst that may reactivate the Hong Kong innovation drug sector, which is currently perceived to be at a relatively safe valuation compared to the Nasdaq [5]

Group 1 - The core viewpoint of the article highlights the recent IPO activities in the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Hong Kong Stock Exchange, with a focus on the performance of newly listed companies and their market valuations [2][8][12] - In the Shanghai Stock Exchange, only one company, Shaanxi Tourism, was listed during the period, with its stock price increasing by 72.18% from the issue price, reaching a market capitalization of approximately 10.7 billion yuan [3][2] - The Hong Kong Stock Exchange saw a more active IPO environment with seven companies listed, including notable performers like Zhipu Huazhang and MiniMax, which saw significant stock price increases of 79.35% and 141.21% respectively [9][10][11] Group 2 - Zhipu Huazhang, an AI company, achieved a market capitalization of approximately 91.7 billion HKD after a 79.35% increase in stock price [9] - MiniMax, another AI-focused company, experienced a remarkable 141.21% increase in stock price, leading to a market capitalization of around 123.1 billion HKD [10] - Other companies like Tian Shu Zhi Xin and Jing Feng Medical also reported substantial stock price increases, indicating a strong interest in tech and healthcare sectors [10][11] Group 3 - Several companies submitted IPO applications during the period, including Zhejiang Borui Biopharmaceutical and Hangzhou Deshi Biotechnology, indicating ongoing interest in the biotech sector [16][26] - The financial data of these companies show varying revenue and profit trends, with Borui Biopharmaceutical projecting revenues of 12.57 billion yuan and 16.23 billion yuan for 2023 and 2024 respectively [24][26] - Deshi Biotech reported revenues of 52.84 million yuan and 70.35 million yuan for the same periods, highlighting the growth potential in the medical imaging sector despite initial losses [27] Group 4 - Companies like Xizi Health and Sanisen Di are focusing on expanding their market presence in the health and nutrition sectors, with Xizi Health projecting revenues of 14.47 billion yuan and 16.92 billion yuan for 2023 and 2024 [36][38] - Sanisen Di aims to enhance its product competitiveness and expand its sales network, reflecting a trend towards innovation in the toy industry [39] - The financial performance of these companies indicates a mix of growth and challenges, with Xizi Health showing a profit increase while Sanisen Di is still working towards profitability [40][38] Group 5 - The article also discusses the performance of established companies like Laoxiangji, which is the largest Chinese fast-food brand, reporting revenues of 45.28 billion yuan in 2022 and projected growth in subsequent years [44] - Laoxiangji's market strategy includes optimizing its supply chain and expanding its store network, which is crucial for maintaining its competitive edge in the fast-food industry [43] - The financial outlook for Laoxiangji shows a steady increase in revenue and profit, indicating a strong market position despite potential risks associated with brand recognition and operational challenges [45][44]

Core Viewpoint - The Sci-Tech Innovation 50 Index experienced a significant decline on January 13, closing at 1469.57 points, down 2.8%, with a trading volume of approximately 104.4 billion yuan [1]. Group 1: Index Performance - The Sci-Tech Innovation Composite Index also fell by 2.66%, closing at 1806.02 points, with a total trading volume of about 375.2 billion yuan [1]. - The average decline for the 600 stocks on the Sci-Tech Board was 1.79%, with an average turnover rate of 4.95% and an average volatility of 6.22% [1]. Group 2: Stock Performance - Rongchang Biopharmaceuticals reached the daily limit, showing the highest increase [2]. - Aerospace Hanyu experienced the largest drop, falling by 18.33% [2]. Group 3: Trading Volume - Cambrian's trading volume was 14.47 billion yuan, ranking first [3]. - ST Pava had the lowest trading volume at 867,000 yuan [3]. Group 4: Turnover Rate - Jianxin Superconducting had the highest turnover rate at 25.97% [4]. - Baile Tianheng recorded the lowest turnover rate at 0.26% [4].

Group 1 - The core point of the news is that TEBIO has experienced a decline in stock price, falling 0.49% to 76.58 CNY per share, with a total market capitalization of 31.259 billion CNY and a cumulative drop of 9.16% over the last four days [1] - TEBIO, established on August 7, 1996, is located in Xiamen, Fujian Province, and specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with 86.85% of its revenue coming from antiviral drugs, 12.87% from blood/cancer drugs, and 0.27% from other sources [1] Group 2 - From the perspective of fund holdings, Huashang Fund has a significant position in TEBIO, with its Huashang Innovation Medical Mixed A fund holding 26,700 shares, unchanged from the previous period, representing 4.31% of the fund's net value [2] - The Huashang Innovation Medical Mixed A fund, established on June 13, 2023, has a current size of 31.7429 million CNY, with a year-to-date return of 25.18% and a one-year return of 23.02%, ranking 3412 out of 8179 and 3511 out of 8148 respectively [2]

瑞银发表报告指，对药明生物2025年全年新增项目数达到209个感到正面，净项目增加数为128个，高于 2024年的119个。此外，药明生物2025年已完成28个PPQ(工艺性能确认)项目，按年增长75%，而2026年 已排程的PPQ项目达到34个。公司表示，2025年营收及利润增长均按计划进行，对2026年前景保持乐 观，并预期2026年将实现按年加速增长。该行认为公司有能力在2026年实现更高的按年增长率，预估营 收将按年增长17%，此增长将获得新签订项目及排程中的PPQ项目的支持。该行维持药明生物目标价为 46.9港元，评级"买入"。 ...

大和发表报告表示，上调对药明生物(2269.HK)目标价，由35.5港元上调至42港元，维持买入评级。该 行上调对药明生物2025年至2027年每股盈利预测1%至5%，基于新签项目预期上升及持续的经营开支杠 杆，以及上调2028至2032年收入预测3%至7%，基于项目增长趋势上调。大和指，药明生物去年净新增 项目128个，多于该行预测的105个。期内毛新增209个项目，半数来自美国客户，三分二为双特异性/多 特异性抗体及ADC。去年新签合约潜在里程碑总额最高可达40亿美元。公司去年完成28个PPQ，今年则 已有34个排期。 ...

1月13日，特宝生物跌0.49%，截至发稿，报76.58元/股，成交1.86亿元，换手率0.59%，总市值312.59亿 元。特宝生物股价已经连续4天下跌，区间累计跌幅9.16%。 成曦累计任职时间9年254天，现任基金资产总规模2501.21亿元，任职期间最佳基金回报131.04%， 任 职期间最差基金回报-67.89%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 易方达上证科创板50ETF（588080）成立日期2020年9月28日，最新规模767.61亿。今年以来收益 12.47%，同类排名587/5517；近一年收益59.83%，同类排名1063/4203；成立以来收益9.04%。 易方达上证科创板50ETF（588080）基金经理为林伟斌、成曦。 截至发稿，林伟斌累计任职时间12年317天，现任基金资产总规模1226.92亿元，任职期间最佳基金回报 80.47%， 任职期间最差基金回报-22.14%。 资料显示，厦门特宝生物工程股份有限 ...